Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II evaluation of Ly156758 in metastatic breast cancer.

Literature DB >> 3412740

Phase II evaluation of Ly156758 in metastatic breast cancer.

A U Buzdar¹, C Marcus, F Holmes, V Hug, G Hortobagyi.

Abstract

Fourteen patients with disseminated breast cancer with primary or secondary resistance to tamoxifen were treated with LY156758. There were no complete or partial responses and 1 patient showed a minor response. These data illustrate that LY156758 did not have significant antitumor activity in patients previously treated with tamoxifen therapy.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1988 PMID： 3412740 DOI： 10.1159/000226637

Source DB: PubMed Journal: Oncology ISSN： 0030-2414 Impact factor: 2.935

Keyword Cloud
Cited

30 in total

Review 1. Effect of SERMs on breast tissue.

Authors: S R Goldstein
Journal: J Endocrinol Invest Date: 1999-09 Impact factor: 4.256

2. Raloxifene: handle with care.

Authors: K I Pritchard; M Levine; B Walley
Journal: CMAJ Date: 2001-07-24 Impact factor: 8.262

Review 3. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Authors: Donald P McDonnell; Suzanne E Wardell
Journal: Curr Opin Pharmacol Date: 2010-12 Impact factor: 5.547

4. Beyond raloxifene for the prevention of osteoporosis and breast cancer.

Authors: V C Jordan
Journal: Br J Pharmacol Date: 2006-11-20 Impact factor: 8.739

Review 5. The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.

Authors: D A Tonetti; V C Jordan
Journal: J Mammary Gland Biol Neoplasia Date: 1999-10 Impact factor: 2.673

6. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

Authors: Hong Liu; Woo-Chan Park; David J Bentrem; Kevin P McKian; Alexander De Los Reyes; Jessica A Loweth; Jennifer MacGregor Schafer; James W Zapf; V Craig Jordan
Journal: J Biol Chem Date: 2001-12-20 Impact factor: 5.157

Phase II evaluation of Ly156758 in metastatic breast cancer.

Review 1. Effect of SERMs on breast tissue.

2. Raloxifene: handle with care.

Review 3. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

4. Beyond raloxifene for the prevention of osteoporosis and breast cancer.

Review 5. The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.

6. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

Review 7. Using human experience to identify drug repurposing opportunities: theory and practice.

Review 8. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Review 9. Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.

10. From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).